Comparative chemopreventive activity of ibuprofen and N-(4-hydroxyphenyl) retinamide against the development and growth of rat mammary adenocarcinomas

Anticancer Research

Volumn 19, Issue 4 B, 1999, Pages 3031-3036

  Alshafie, Galal A ^a   Harris, Randall E ^a,b   Robertson, Fredika M ^a,b   Parrett, Michelle L ^a,b   Ross, Mary ^a,b   Abou Issa, Hussein ^a,b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Cyclooxygenase; Ibuprofen; NSAIDS; Prostaglandins; Rat mammary cancer; Retinoids

Indexed keywords

DIMETHYLBENZ[A]ANTHRACENE; FENRETINIDE; IBUPROFEN;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CANCER GROWTH; CANCER INCIDENCE; CANCER PREVENTION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; FEMALE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; ANTICARCINOGENIC AGENTS; FEMALE; FENRETINIDE; IBUPROFEN; MAMMARY NEOPLASMS, EXPERIMENTAL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0033451826     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Kune GA, Kune S, and Watson LF: Colorectal cancer risk, chronic illnesses, operations and medications. Case control results from the Melbourne Colorectal Cancer Study. Cancer Res 48: 4399-4404, 1988.
2. Thun MJ, Namboodiri MM, and heath CW: Aspirin use and reduced risk of fatal colon cancer. N Engl J Medt 325: 1593-1596, 1991.
3. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, and Shapiro SA: A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large bowel cancer. J Natl Cancer Inst 83: 355-358, 1991.
4. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, Hoover R, and Fraumeni JF: Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85: 307-311, 1993.
5. Greenburg ER, Baron JA, Freeman DH, Mandel JS, and Haile R: Reduced risk of large-bowel adenomas among aspirin users. The polyp Prevention Study Group. J Natl Cancer Inst 85: 912-916, 1993.
6. Schreinemachers DM, and Everson RB: Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5: 138-146, 1994.
7. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, and Willett WC: Aspirin use and the risk of colorectal cancer and adenoma in male health professionals. Ann Intern Med 121: 241-246, 1994.
8. Muscat JE, Stellman SD, and Wynder EL: Analgesic use and colorectal cancer. Prev Med 24: 110-112, 1995.
9. Rosenberg L: Nonsteroidal Anti-inflammatory Drugs and Cancer. Prev Med 24: 107-109, 1995.
10. Reddy BS, Tokuma K, Kulkarni N, Aligia C, and Kelloff G: Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis 13: 1019-1023, 1992.
11. Kelloff GJ, Crowell JA, Boone CW, Steele VE, Lubet RA, Greenwald P, Alberts DS, Covey JM, Doody LA, Knapp GG, et al: Clinical development plan: Ibuprofen. J Cell Biochem 20 (suppl): 197-204, 1994.
12. Steele VE, Moon RC, Lubet RA, Grubbs CJ, Reddy BS, Wargovich M, McCormick DL, Pereira MA, Crowell JA, Bagheri D, Sigman CC, Boone CW, and Kelloff GJ: Preclinical efficacy evaluation of potential chemopreventivc agents in animal carcinogenesis models: methods and results from the NCI chemoprevention drug development program. J Cell Biochem 20 (suppl): 32-54, 1994.
13. Ip MM, Mazzer C, Watson D, Carter C, and Ip C: The effect of eicosanoid synthesis inhibitors on DMBA-induced rat mammary carcinogenesis. Proc Am Assoc Cancer Res 30: 721, 1989.
14. Carter CA, Milholand RJ, shea W, and Ip MM: Effect of prostaglandin synthetase inhibitor indomethacin on 7,12-dimethylbenz[a] anthracene-induced mammary tumorigenesis in rat fed different levels of fat. Cancer Res 43: 3559-3562, 1983.
15. Castonguay A, Bilodeau JF, Jalbert G, Wang M, and Chung FL: Inhibition of lung tumorigenesis by Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Proc Am Assoc Cancer Res 34: 558, 1993.
16. Duperrone C, and Castonguay A: Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis 18(5): 1001-1006, 1997.
17. Perrira MA, Barnes LH, Steele VE, Kelloff GV, and Lubet RA: Piroxicam-induced regression of azoxymethane-induced aberrant crypt foci and prevention of colon cancer in rats. Carcinogenesis 17: 373-376, 1996.
18. Spagnesi MT, Tonelli F, Dolara P, Caderni G, Anastasi A, and Bianchini F. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after Sulindac treatment. Gastroenterology 106: 362-366, 1994.
19. Paganini-Hill A, Chao A, Ross RK, Henderson BE: Aspirin use and chronic disease: a cohort studyoftheelderly. Brit Med J 229: 1247-1250, 1989.
20. Egan KM, Stampfer MJ, Giovannuci E et al: Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 88, 988-993, 1991.
21. Harris RE, Namboodiri KK, and Farrar WB: Epidemiological study of non-inflammatory drugs and breast cancer. Oncol Rep 2: 591-592, 1995.
22. Harris RE, Namboodiri KK, Stellman SD, and Wynder EL: Breast cancer and NSAID Use: heterogeneity of effect in a case-control study. Prev Med 24: 119-120, 1995.
23. Harris RE, Namboodiri KK, and Farrar WB: Nonsteroidal anti-inflammatory drugs and breast cancer. Epidemiology 7: 203-205, 1996.
24. Robertson FM, Parrett ML, Joarder FS, Ross M, Abou-Issa H, Alshafie G, and Harris RE: Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinomas. Cancer Lett 122: 165-175, 1998.
25. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, and Vane JR: Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 90: 11693-11697, 1994.
26. Kujubu DA, Reddy ST, Fletcher BS and Herschman HR: Expression of the protein product of the prostaglandin synthase-2/T1510 gene in mitogen stimulated Swiss 3T3 cells. J Biol Chem 268: 5425-5430, 1993.
27. Herschman HR: Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer Metastasis Rev 13: 241-256, 1994.
28. DuBois RN, Awad J, Morrow J, Roberts LJ, and Bishop P: Regulation of eicosanoid production and mitogenesis by transforming growth factor α and phorbol ester. J Clin Invest 93: 493-498, 1994.
29. O'Neill GP, and Ford-Hutchinson AW: Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS 330(2): 156-160, 1993.
30. Hwang D, Scollard D, Byrne J, and Levine E: Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90: 455-460, 1998.
31. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, and Jothy S: Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 55: 2556-2559, 1995.
32. Parrett ML, Harris RE, Joarder FS, Clausen KP, and Robertson FM: Cyclooxygenase-2 gene expression in human breast cancer. Int J Oncol 10: 503-507, 1997.
33. Honn KV, Bockman RS and Marnett LJ: Prostaglandins and cancer, a review of tumor initiation through tumor metastasis. Prostaglandins 21: 833-864, 1981.
34. 2 production and metabolism in human breast cancer cells and fibroblasts. Regulation by inflammatory mediators. Br J Cancer 72: 1412-1419, 1995.
35. Joarder FS, Abou-Issa H, Robertson FM, Parrett ML, Alshafie G, and Harris RE: Growth arrest of DMBA-induced mammary carcinogenesis with Ibuprofen treatment in female Sprague-Dawley rats. Oncol Rep 4: 1271-1273, 1997.
36. Abou-Issa H, Curley RW, Panigot MJ, Tanagho SN, Sidhu BS, and Alshafie GA: Chemotherapeutic evaluation of N-(-4-Hydroxyphenyl) Retinamide-O-Glucuronide in the rat mammary tumor model. Anticancer Res 17: 3335-3340, 1997.
37. Abou-Issa H, Webb TE, Minton JP, and Moeschberger M: Chemotherapeutic evaluation of glucurate:N-(4-hydroxyphenyl)-retinamide combination in the rat mammary tumor model. J Natl Cancer Inst 81: 1820-1823, 1998.
38. Abou-Issa H and Duruibe V: Anticarcinogenic effects of retinoids on 7,12-dimethylbenz (a) anthracene-induced mammary tumor induction and its relationship to cyclic AMP-dependent protein kinase. Biochem Biophys Res Commun 135: 116-123, 1986.
39. Bhatnagar R, Abou-Issa H, Curley RW, Moeschberger ML and Webb TE: Growth suppression of human breast cancer cells in culture by N-(4-hydroxyphenyl) retinamide, its glucuronide and through synergism with glucarate. Biochem Pharmacol 41: 1471-1477, 1991.
40. Klufeld DM, Welch CB, Davis MJ: Determination of degree of energy restriction necessary to reduce DMBA-induced mammary tumorigenesis in rats during the promotion phase. J Nutr 119: 286-291, 1989.
41. Shah A, and Jung D: Dose-dependent pharmacokinetics of Ibuprofen in the rat. Drug Metab Dispos 15: 151-154, 1987.
42. Davis NM, Wright MR, and Jamali F: Anti-inflammatory drug-induced small intestinal permeability: the rat is a suitable model. Pharmaceut Res 11: 1652-1656, 1994.
43. Lupulescu A: Prostaglandins, their Inhibitors and cancer. Prostaglan Leuk Essent Fatty Acids 45(2): 83-94, 1996.
44. Marnett LJ: Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 52: 5575-5589, 1992.
45. Tsujii M, DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells over expressing prostaglandin endoperoxide synthase-2. Cell 83: 493-501, 1995.
46. Lu X, Xie W, Reed D: Non-steroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenase in chicken embryo fibroblasts. Proc Natl Acad Sci USA 92: 7961-7965, 1995.
47. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, and DuBois RN: Upregulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188, 1994.
48. Liu XH, and Rose DP: Differential expression and regulation of cyclooxygenase-1 and 2 in two human breast cancer cell lines. Cancer Res 56: 5125-5127, 1996.
49. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, Graham-Lorence S, Amarneh B, Ito Y, Fisher CR, Michael MD, Mendelson CR, and Bulun SE: Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocrine Rev 15: 342-355, 1994.
50. 2 via cyclic AMP, leading to activation of promotor II of the CYP19 (aromatase) gene. Endocrinology 137: 5739-5742, 1996.
51. Dickson RB, and Lippman ME: Molecular basis of breast cancer. In: The Molecular Basis of Cancer. Mendelson J, Howley PM, Israel MA, Liotta LA (eds). W.B. Saunders Company, Philadelphia, PA, 1995.
52. Tahanont MV, and Gee MH: The effects of cyclooxygenase inhibition on chemoluminescence and aggregation in sheep neutrophils. Prostagland Leuk Med 24: 139-149, 1986.
53. Marnett LJ: Generation of mutagens during arachidonic acid metabolism. Cancer Metastasis Rev 13: 241-256, 1994.
54. Fulton AM, and Levy JG: Inhibition of murine tumor growth and prostaglandin synthesis by Indomethacin. Int J Cancer 26: 669-763, 1980.
55. Fulton AM: In vivo effects of indomethacin on the growth of murine mammary tumors. Cancer Res 44: 2416-2420, 1984.
56. McCormick DL, Madigan MJ, and Moon RC: Modulation of rat mammary carcinogenesis by Indomethacin. Cancer Res 45: 1803-1808, 1985.
57. Lee PP, Ip MM: Regulation of proliferation of rat mammary tumor cells by inhibitors of cyclooxygenase and lipooxygenase. Prostagland Leuk Essent Fatty Acids 45: 21-31, 1992.
58. Ara G, and Teicher BA: Cyclooxygenase and lipooxygenase Inhibitors in cancer therapy. Prostagland Leuk Essent Fatty Acids 54: 2-16, 1996.
59. Steel GG: Growth kinetics oftumors. Oxford Univ Press, London, 1977, pp 5-25.
60. Woolson RF: Statistical methods for the analysis of biomedical data. New York, John Wiley & sons, 1987, pp 327-344.
61. Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, Inoue H, Dannenberg AJ: Retinoids suppress phorbol ester-mediated induction of cyclooxygenase-2. Cancer Res 57: 1081-1085, 1997.